Influence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation. - Wikidata - wikimedia - TriplyDB

Influence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation.

Influence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation.

http://www.wikidata.org/entity/Q35112269

about

Salvage therapy with everolimus reduces the severity of treatment-refractory chronic GVHD without impairing disease control: a dual center retrospective analysis.Failure-free survival after initial systemic treatment of chronic graft-versus-host disease Autologous apoptotic cells preceding transplantation enhance survival in lethal murine graft-versus-host models.Association of severity of organ involvement with mortality and recurrent malignancy in patients with chronic graft-versus-host disease A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation.How we treat chronic graft-versus-host disease.Treatment of chronic graft-versus-host disease: Past, present and future.Factors predictive of relapse of acute leukemia in children after allogeneic hematopoietic cell transplantation.Graft-versus-host disease induced graft-versus-leukemia effect: greater impact on relapse and disease-free survival after reduced intensity conditioning Allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia in adults Relapse after Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes: Analysis of Late Relapse Using Comparative Karyotype and Chromosome Genome Array Testing Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation.Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease.Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation Allogeneic hematopoietic cell transplantation following minimal intensity conditioning: predicting acute graft-versus-host disease and graft-versus-tumor effects.Incidence, risk factors, and outcomes of sclerosis in patients with chronic graft-versus-host disease.Pharmacologic prophylaxis regimens for acute graft-versus-host disease: past, present and future.BCR-ABL1 transcripts (MR4.5) at post-transplant 3 months as an early predictor for long-term outcomes in chronic myeloid leukemia.Optimizing management of myelodysplastic syndromes post-allogeneic transplantation.Clinical trials in chronic myeloid leukemia.Comparison of graft-versus-host disease-free, relapse-free survival of transplantation using matched sibling donor, matched unrelated donor or unrelated cord blood after myeloablative conditioning for adult patients with hematological malignancies.The role of novel immunotherapies in non-Hodgkin lymphoma.Prophylaxis and treatment of GVHD after allogeneic haematopoietic SCT: a survey of centre strategies by the European Group for Blood and Marrow Transplantation.Influence of Age on Acute and Chronic GVHD in Children Undergoing HLA-Identical Sibling Bone Marrow Transplantation for Acute Leukemia: Implications for Prophylaxis.Results of a phase 1 study of quizartinib as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic stem cell transplant.Acute mechanical hemolysis as a complication of extracorporeal photopheresis in a low-weight child.Occurrence of graft-versus-host disease increases mortality after umbilical cord blood transplantation for acute myeloid leukaemia: a report from Eurocord and the ALWP of the EBMT.Success of Immunosuppressive Treatments in Patients with Chronic Graft-versus-Host Disease.Mild chronic graft-versus-host disease may alleviate poor prognosis associated with FLT3 internal tandem duplication for adult acute myeloid leukemia following allogeneic stem cell transplantation with myeloablative conditioning in first complete re

P2860

Q33416874-DA37FEF1-609F-4A46-B5FE-C31EB1AB47FF Q34077787-DA3509B7-860D-4040-9ED7-8AC6869979AA Q34170406-D1603C71-B621-4EB2-AAAD-D615B3A32D63 Q34272547-0D4FEC1D-90BB-4EAB-AFDA-C6CCBCCE1578 Q34272554-02AC6A81-DC7C-428D-9ED5-AE62FFF14356 Q35004923-897C2413-145C-477D-AFA8-E781B745DC49 Q35524687-895A352B-4E30-46CD-A2CD-574D2E649E15 Q35752737-FAC69772-8F1B-4FA0-B2A6-FBAFF04D5A2F Q36319726-39DA0332-0E61-4393-9F79-9E4311AF138E Q36461915-3CE73FBE-0E45-4B66-A63C-3C2CE2382176 Q36635154-41278E2C-BA0A-4D44-B295-DCC713EA5B93 Q36700499-951FEB27-F70B-4F4D-A455-AA2C42DA2B0F Q36709850-9A50C20C-E00C-42F9-97CA-97F124EE305A Q36763834-1A82A181-C85B-4AC3-9FDB-256B2A1C7788 Q36774150-D1C17C42-2FC6-4FDE-B998-94C05D3BCCFD Q36945976-C0E0464D-AE46-4ED2-91D8-F0D512C7937B Q36980277-EBC857AB-7478-470A-AC8C-56597021271D Q37559148-06BBBC3E-D378-4BF4-AA70-62AD7B5035EE Q37955235-29B42D6B-D725-416E-8AFF-77B0E482F13C Q37994134-DAA8AE34-ACF4-434F-BB2E-5A6FDA9FE305 Q40106226-3C40D262-41AB-4F5E-8BF6-7120A674E143 Q41695080-B9E7AC4F-84EB-40E9-88D7-C3117E3C88CB Q44243900-5229422E-44A8-4FAB-8B03-46588FA978A3 Q45874732-5C229463-193D-425A-ABC8-DD73B94BDDDC Q46721176-D6446771-6F3F-46EF-B11E-ABDE1A5CE7E0 Q47255174-D9D6B8B6-2732-45AD-B0C2-B0F003DA78E1 Q47865655-A982D65B-94FA-4E43-8B04-B4869ED66FD1 Q50043532-F8760C9D-CF69-4D5B-B4D8-4F80FCE680A2 Q54275690-94E8004E-06E5-47EE-8FC1-BF442A390D75

P2860

Influence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation.

http://www.wikidata.org/entity/Q35112269

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Influence of immunosuppressive ...... opoietic cell transplantation.

@ast

Influence of immunosuppressive ...... opoietic cell transplantation.

@en

type

label

Influence of immunosuppressive ...... opoietic cell transplantation.

@ast

Influence of immunosuppressive ...... opoietic cell transplantation.

@en

prefLabel

Influence of immunosuppressive ...... opoietic cell transplantation.

@ast

Influence of immunosuppressive ...... opoietic cell transplantation.

@en

P1433

Q35112269-01A4549B-601A-4958-A210-4EC9E5B13C4E

P1476

Q35112269-2BA0DD85-F469-41F4-B8ED-75E06AF3A203

P2093

Q35112269-1D7BA260-65B0-4EDB-9353-ED09D4B03CD6

Q35112269-3EDFA1C9-8E98-4F8A-ACDD-D965BB6813B4

Q35112269-435E4992-7055-4CCA-BA55-0089C79E7BB9

Q35112269-8575DFC9-4515-4316-985B-408ED2E98A99

Q35112269-EB3EEBE4-9909-416A-81A1-2549DA544FED

Q35112269-FCF50FC9-E48A-4FE2-B30C-C0ECCBD70577

P2860

Q35112269-1D19D57C-744C-4786-9839-E23C53772002

Q35112269-359820C2-3331-4FC9-8BC6-84D3D91C5538

Q35112269-38133A63-D4ED-42BA-AAF0-BE77B9589203

Q35112269-456A1433-074A-4100-A6C8-5910DE93D35C

Q35112269-4F6DA9F1-E213-4B2B-AE6F-4EC0728694DF

Q35112269-4FC58610-1F6A-43B0-A56D-C8538993D350

Q35112269-52AFD814-EA90-4729-80FE-2DA34EE37488

Q35112269-56EEF616-1D61-4537-86DC-0167DE195E2C

Q35112269-781A7444-0060-41E5-8348-A99EE05C189E

Q35112269-786687A0-8DB2-4932-8AE8-A3B3C09AA24D

P304

Q35112269-B6EF64B1-B668-410C-B326-5003008DCADE

P31

Q35112269-B0ED9CA0-67E6-454D-A1DD-F58556FF9FF7

P356

Q35112269-DF9E4158-8232-4CF1-90E5-B0BE458A1B06

P407

Q35112269-B16BD6FF-BE8E-434F-A2D8-3CF09939A978

P433

Q35112269-B237AD3A-E69D-443A-A025-4B83BD333663

P478

Q35112269-054F6AD8-6E52-4EE4-96CD-F8EBEA4A3C92

P50

Q35112269-0E81E0DB-5317-4DF4-AC5A-40D9EB28E85F

Q35112269-397D3B85-9974-4B60-998F-38AD6232001A

Q35112269-C0464DAD-5BE6-42E9-B67D-E19F9581C634

Q35112269-F0D2E5F2-2A56-4B71-8902-4F2D1E95AA03

P577

Q35112269-3529AF5A-E6C0-4430-8910-652D40BF8C05

P698

Q35112269-AD142206-3BB6-4519-806F-1786386236E3

P932

Q35112269-C695B064-C36F-4AF6-B727-119781E2A348

P356

BLOOD-2011-01-330217

P1433

P1476

Influence of immunosuppressive ...... opoietic cell transplantation.

@en

P2093

Edus H Warren

http://www.w3.org/2001/XMLSchema#string

Mary E D Flowers

http://www.w3.org/2001/XMLSchema#string

Paul A Carpenter

http://www.w3.org/2001/XMLSchema#string

Paul J Martin

http://www.w3.org/2001/XMLSchema#string

Stephanie J Lee

http://www.w3.org/2001/XMLSchema#string

Yoshihiro Inamoto

http://www.w3.org/2001/XMLSchema#string

P2860

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants

Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation.

Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation.

NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Tr

Haematopoietic cell transplantation as immunotherapy.

Introduction to the reports from the National Cancer Institute First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.

Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.

Reduced mortality after allogeneic hematopoietic-cell transplantation.

National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report.

Graft-versus-leukemia effects of transplantation and donor lymphocytes.

P304

456-463

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2011-01-330217

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

118

http://www.w3.org/2001/XMLSchema#string

P50

Rainer F. Storb

Frederick R. Appelbaum

Hans Joachim Deeg

P577

2011-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21633087

http://www.w3.org/2001/XMLSchema#string

P932

3138695

http://www.w3.org/2001/XMLSchema#string